Program Leaders

项目负责人

• 批准号: 7714406
• 负责人: KELVIN P. LEE
• 金额: $ 12.31万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-28 至 2013-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7714406
• 关键词: Address; Administrator; American Association of Cancer Research; American Society of Clinical Oncology; Association of American Cancer Institutes; Awareness; Cancer Center Support Grant; Caring; Cells; Clinical; Clinical Research; Clinical Trials; Comprehensive Cancer Center; Daily; Decision Making; Development; Education; Faculty; Funding; Growth; Image; Institutes; Leadership; Malignant Neoplasms; Marshal; Mayo Clinic Cancer Center; Molecular Target; National Comprehensive Cancer Network; Numbers; Ohio; Outpatients; Parents; Participant; Play; Population; Population Sciences; Positioning Attribute; Process; Program Development; Program Evaluation; Prostate; Recruitment Activity; Research; Research Personnel; Resource Sharing; Role; Series; Services; Strategic Planning; Stress; Therapeutic; Time; Universities; Vision; Walkers; Work; anticancer research; base; cancer Biomedical Informatics Grid; cancer prevention; experience; health disparity; member; programs; symposium; trend

The 3 new senior leaders, Dr. Gudkov, Dr. Adjei, and Mr. Walker, bring fresh ideas and perspectives to the Institute as well as a wealth of scientific program development, and administrative leadership experience garnered from their involvement at other major NCI-designated cancer programs (Case Comprehensive Cancer Center, Mayo Clinic Cancer Center and the Ohio State University Comprehensive Cancer Center, respectively). Each of the Senior Leaders also plays a pivotal role in a CCSG Programs or Shared Resources. Dr. Adjei serves as Leader of the Molecular Targets and Experimental Therapeutics (MTET) and oversees Clinical Research Services, Dr. Gudkov is Leader of the Cell Stress and Biophysical Therapies (CSBT) Program, and Dr. James Marshall leads the Cancer Prevention and Population Sciences (CPPS) program. Dr. Candace Johnson is an active participant in the Prostate Program and MTET, while Dr. Trump participates in the Molecular Targets and Experimental Therapeutics Program. Mr. Walker serves as the CCSG Administrator and oversees the CCSG shared resources. All members of the Senior Leadership Team are active in the faculty recruitment process, serving as chairs or members of search committees. Further they are also involved in coordinating the EAB meetings, annual retreats, symposia/seminar series and participating in development activities. Each of these leaders is also active in national cancer research forums and well integrated into leadership and committee positions in these external arenas (ASCO, AACR, AACI, NCCN, NCI [caBIG, IRGs, parent committees]) assuring their awareness of and participation in deliberations regarding important national topics in cancer research, care and education and guaranteeing RPCI awareness of and leadership in the national trends. The Senior Leadership team interacts informally on a daily basis and meets formally on a weekly basis in the primary administrative leadership forum known as the RPCI Executive Council. Chaired by Dr. Trump, the Executive Council is the major decision-making body of the Institute, responsible for the on-going oversight of the RPCI and addressing all functional issues raised by its members. In addition, the Senior Leadership participates on the CCSG Steering Committee, a committee that meets monthly and includes the research program leaders as well as leaders of important CCSG and Institute initiatives [e.g., Imaging Development, Health Disparities]. The CCSG Steering Committee, chaired by Dr. Trump, provides a venue for strategic planning, program evaluation, membership review and approval and review of existing and proposed shared resources. Although there are several other venues where the Senior Leadership participates, it is through these two committees that primary decision-making is accomplished. There has been dramatic growth in RPCI during the last funding cycle. Over this funding cycle (2002 to 2006) the Senior Leadership team worked together to recruit more than 100 cancer investigators and clinicians, increase NCI funding by 74%, increase accruals to therapeutic investigator-initiated clinical trials and increase in out patient volume by 42% over this time period. As the number of cancer-focused basic, translational, clinical and population investigators at the RPCI have grown, four new Shared Resources have been established to support the needs of the membership with three more now in development. It is anticipated that the current Senior Leadership team will continue this successful trajectory via developing and executing longterm vision and strategic planning for the Institute.

3位新的高级领导人，古德科夫博士，阿杰博士和步行者先生，带来了新的想法和观点， 以及丰富的科研项目开发和行政领导经验 从他们参与其他主要的国家癌症研究所指定的癌症项目中获得（病例综合 癌症中心、马约诊所癌症中心和俄亥俄州州立大学综合癌症中心， 分别）。 每个高级领导者还在CCSG计划或共享资源中发挥关键作用。阿吉博士 担任分子靶点和实验治疗（MTET）的负责人，并监督临床 Gudkov博士是细胞应激和生物物理疗法（CSBT）项目的负责人， 博士詹姆斯马歇尔领导癌症预防和人口科学（CPPS）计划。坎迪斯医生 约翰逊是前列腺计划和MTET的积极参与者，而特朗普博士则参与了 分子靶点和实验治疗学计划。步行者先生担任CCSG管理员 并监督CCSG共享资源。高级领导小组的所有成员都积极参与 教师招聘过程中，担任主席或搜索委员会的成员。此外，他们还 参与协调EAB会议、年度务虚会、专题讨论会/研讨会系列，并参与 发展活动。这些领导人中的每一位也活跃在国家癌症研究论坛上， 整合到这些外部领域（ASCO、AACR、AACI、NCCN、NCI）的领导和委员会职位中 [caBIG、IRG、家长委员会]）确保他们了解并参与有关 癌症研究、护理和教育方面的重要国家课题，并保证RPCI认识和 引领全国潮流。 高级领导团队每天进行非正式互动，每周在 主要行政领导论坛，称为RPCI执行理事会。由特朗普博士主持， 执行理事会是研究所的主要决策机构，负责持续监督 该委员会还负责处理其成员提出的所有职能问题。此外，高级领导人 参加CCSG指导委员会，该委员会每月举行一次会议，包括研究 项目负责人以及重要CCSG和研究所倡议的负责人[例如，图像开发， 健康差异]。由特朗普博士主持的CCSG指导委员会提供了一个战略性的场所。 规划、计划评估、成员资格审查和批准以及审查现有和拟议的共享 资源虽然高级领导人还参加了其他几个会议，但通过 这两个委员会的主要决策已经完成。 在上一个供资周期中，区域生产能力倡议有了急剧增长。在本供资周期（2002年至2006年） 高级领导团队共同努力，招募了100多名癌症研究人员和临床医生， 将NCI资金增加74%，增加治疗研究者发起的临床试验的应计费用，并增加 在这段时间内，门诊病人数量减少了42%。作为一些癌症的重点基本，翻译， RPCI的临床和人口研究人员已经增加，四个新的共享资源已经 为满足会员国的需求而设立，目前正在开发另外三个。预计各国 目前的高级领导团队将通过制定和执行长期战略， 研究所的愿景和战略规划。